Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries
Ian J Begeman, Joseph Lykins, Ying Zhou, Bo Shiun Lai, Pauline Levigne, Kamal El Bissati, Kenneth Boyer, Shawn Withers, Fatima Clouser, A Gwendolyn Noble, Peter Rabiah, Charles N Swisher, Peter T Heydemann, Despina G Contopoulos-Ioannidis, Jose G Montoya, Yvonne Maldonado, Raymund Ramirez, Cindy Press, Eileen Stillwaggon, François Peyron, Rima McLeod, Ian J Begeman, Joseph Lykins, Ying Zhou, Bo Shiun Lai, Pauline Levigne, Kamal El Bissati, Kenneth Boyer, Shawn Withers, Fatima Clouser, A Gwendolyn Noble, Peter Rabiah, Charles N Swisher, Peter T Heydemann, Despina G Contopoulos-Ioannidis, Jose G Montoya, Yvonne Maldonado, Raymund Ramirez, Cindy Press, Eileen Stillwaggon, François Peyron, Rima McLeod
Abstract
Background: Congenital toxoplasmosis is a serious but preventable and treatable disease. Gestational screening facilitates early detection and treatment of primary acquisition. Thus, fetal infection can be promptly diagnosed and treated and outcomes can be improved.
Methods: We tested 180 sera with the Toxoplasma ICT IgG-IgM point-of-care (POC) test. Sera were from 116 chronically infected persons (48 serotype II; 14 serotype I-III; 25 serotype I-IIIa; 28 serotype Atypical, haplogroup 12; 1 not typed). These represent strains of parasites infecting mothers of congenitally infected children in the U.S. 51 seronegative samples and 13 samples from recently infected persons known to be IgG/IgM positive within the prior 2.7 months also were tested. Interpretation was confirmed by two blinded observers. A comparison of costs for POC vs. commercial laboratory testing methods was performed.
Results: We found that this new Toxoplasma ICT IgG-IgM POC test was highly sensitive (100%) and specific (100%) for distinguishing IgG/IgM-positive from negative sera. Use of such reliable POC tests can be cost-saving and benefit patients.
Conclusions: Our work demonstrates that the Toxoplasma ICT IgG-IgM test can function reliably as a point-of-care test to diagnose Toxoplasma gondii infection in the U.S. This provides an opportunity to improve maternal-fetal care by using approaches, diagnostic tools, and medicines already available. This infection has serious, lifelong consequences for infected persons and their families. From the present study, it appears a simple, low-cost POC test is now available to help prevent morbidity/disability, decrease cost, and make gestational screening feasible. It also offers new options for improved prenatal care in low- and middle-income countries.
Conflict of interest statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: Dr. Rima McLeod is working on a literature review for Sanofi Pasteur.
Figures
References
- Lykins J, Wang K, Wheeler K, Clouser F, Dixon A, El Bissati K, et al. Understanding Toxoplasmosis in the United States Through "Large Data" Analyses. Clin Infect Dis. 2016;63(4):468–75. doi:
- McLeod R, Lee D, Clouser F, Boyer K. Toxoplasmosis in the Fetus and Newborn Infant In: Stevenson DK, Cohen RS, Sunshine P, editors. Neonatology: Clinical Practice and Procedures. 1st ed New York: McGraw Hill; 2015. p. 821–76.
- McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz. 2009;104(2):320–44.
- Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47(4):554–66. doi:
- Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ. 2013;91(7):501–8. doi:
- McPhillie M, Zhou Y, El Bissati K, Dubey J, Lorenzi H, Capper M, et al. New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Sci Rep. 2016;6:29179 doi:
- El Bissati K, Chentoufi AA, Krishack PA, Zhou Y, Woods S, Dubey JP, et al. Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight. 2016;1(15):e85955 doi:
- Mohle L, Israel N, Paarmann K, Krohn M, Pietkiewicz S, Muller A, et al. Chronic Toxoplasma gondii infection enhances beta-amyloid phagocytosis and clearance by recruited monocytes. Acta Neuropathol Commun. 2016;4:25 doi:
- Perry CE, Gale SD, Erickson L, Wilson E, Nielsen B, Kauwe J, et al. Seroprevalence and Serointensity of Latent Toxoplasma gondii in a Sample of Elderly Adults With and Without Alzheimer Disease. Alzheimer Dis Assoc Disord. 2016;30(2):123–6. doi:
- Ngoungou EB, Bhalla D, Nzoghe A, Darde ML, Preux PM. Toxoplasmosis and epilepsy—systematic review and meta analysis. PLoS Negl Trop Dis. 2015;9(2):e0003525 doi:
- Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Kopp CB, et al. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis. 2013;56(9):1223–31. doi:
- Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E. Congenital toxoplasmosis in Austria: prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis. In press, 2017.
- Hotop A, Hlobil H, Gross U. Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2012;54(11):1545–52. doi:
- Kieffer F, Wallon M, Garcia P, Thulliez P, Peyron F, Franck J. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J. 2008;27(1):27–32. doi:
- Stillwaggon E, Carrier CS, Sautter M, McLeod R. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 2011;5(9):e1333 doi:
- Peyron F, Mc Leod R, Ajzenberg D, Contopoulos-Ioannidis D, Kieffer F, Mandelbrot L, et al. Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches. PLoS Negl Trop Dis. 2017;11(2):e0005222 doi:
- Chapey E, Wallon M, Peyron F. Evaluation of the LDBIO point of care test for the combined detection of toxoplasmic IgG and IgM. Clin Chim Acta. 2017;464:200–1. doi:
- McLeod R, Boyer KM, Lee D, Mui E, Wroblewski K, Karrison T, et al. Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981–2009). Clin Infect Dis. 2012;54(11):1595–605. doi:
- Contopoulos-Ioannidis D, Wheeler KM, Ramirez R, Press C, Mui E, Zhou Y, et al. Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015;61(12):1815–24. doi:
- Pomares C, Montoya JG. Laboratory Diagnosis of Congenital Toxoplasmosis. J Clin Microbiol. 2016;54(10):2448–54. doi:
- Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ. 1994;308(6943):1552
- Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ. 1994;309(6947):102
- Dhakal R, Gajurel K, Pomares C, Talucod J, Press CJ, Montoya JG. Significance of a Positive Toxoplasma Immunoglobulin M Test Result in the United States. J Clin Microbiol. 2015;53(11):3601–5. doi:
- Li X, Pomares C, Gonfrier G, Koh B, Zhu S, Gong M, et al. Multiplexed Anti-Toxoplasma IgG, IgM, and IgA Assay on Plasmonic Gold Chips: towards Making Mass Screening Possible with Dye Test Precision. J Clin Microbiol. 2016;54(7):1726–33. doi:
- Pomares C, Zhang B, Arulkumar S, Gonfrier G, Marty P, Zhao S, et al. Validation of IgG, IgM multiplex plasmonic gold platform in French clinical cohorts for the serodiagnosis and follow-up of Toxoplasma gondii infection. Diagn Microbiol Infect Dis. 2017;87(3):213–8. doi:
- Sabin AB, Feldman HA. Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science. 1948;108(2815):660–3. doi:
- Naot Y, Remington JS. An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis. 1980;142(5):757–66.
- Desmonts G, Naot Y, Remington JS. Immunoglobulin M-immunosorbent agglutination assay for diagnosis of infectious diseases: diagnosis of acute congenital and acquired Toxoplasma infections. J Clin Microbiol. 1981;14(5):486–91.
- Stepick-Biek P, Thulliez P, Araujo FG, Remington JS. IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis. J Infect Dis. 1990;162(1):270–3.
- Pelloux H, Brun E, Vernet G, Marcillat S, Jolivet M, Guergour D, et al. Determination of anti-Toxoplasma gondii immunoglobulin G avidity: adaptation to the Vidas system (bioMerieux). Diagn Microbiol Infect Dis. 1998;32(2):69–73.
Source: PubMed